CDK4 and non-small cell lung carcinoma: The CDK4/6 inhibitor abemaciclib did not show clinical activity, with a PFS of 2.4 months, compared to the 4.2-month PFS of docetaxel, in the second-line treatment of stage IV NSCLC (25).